BE400671A - - Google Patents
Info
- Publication number
- BE400671A BE400671A BE400671DA BE400671A BE 400671 A BE400671 A BE 400671A BE 400671D A BE400671D A BE 400671DA BE 400671 A BE400671 A BE 400671A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- acid
- phenylchinolineorthocarbonic
- preparation
- monoethanolamine
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 11
- 229940116269 uric acid Drugs 0.000 claims description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 9
- 229960002449 glycine Drugs 0.000 claims description 9
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- -1 phenylchinolin-orthocarbonic acid Chemical compound 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 235000005772 leucine Nutrition 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 8
- 229940096919 glycogen Drugs 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 238000008114 Uric Acid Assay Methods 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- CWVZGJORVTZXFW-UHFFFAOYSA-N [benzyl(dimethyl)silyl]methyl carbamate Chemical compound NC(=O)OC[Si](C)(C)CC1=CC=CC=C1 CWVZGJORVTZXFW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE400671A true BE400671A (enrdf_load_html_response) |
Family
ID=66746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE400671D BE400671A (enrdf_load_html_response) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE400671A (enrdf_load_html_response) |
-
0
- BE BE400671D patent/BE400671A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0263861A1 (fr) | Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic. | |
| BE834794A (fr) | Acide 3-trihydroxygermano-propionique | |
| EP0354836B1 (fr) | Polymères iodés à squelette dextrane, leurs procédés de préparation et leurs applications comme produits de contraste | |
| EP0344202B1 (fr) | Polymeres iodes, leurs procedes de preparation et leurs applications comme produits de contraste | |
| FR2945448A1 (fr) | Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre. | |
| BE400671A (enrdf_load_html_response) | ||
| CA1095067A (fr) | Sels d'hydrocarbyl-thio-ethylamines et leurs applications | |
| CH625221A5 (enrdf_load_html_response) | ||
| US2276882A (en) | Gastric mucin product and process for producing same | |
| CH627463A5 (en) | Salts of basic amino sugars or of basic amino acids | |
| FR2518880A1 (fr) | Compositions therapeutiques a activite choleretique, contenant a titre de principe actif, des derives de l'acide cholanique | |
| BE704075A (enrdf_load_html_response) | ||
| BE522018A (enrdf_load_html_response) | ||
| CH259253A (fr) | Procédé de préparation de l'oléate d'acétylcholine. | |
| Lewis | The Separation of Fatty Acids | |
| CN118615494A (zh) | 盐酸丁卡因肠镜润滑剂 | |
| BE572026A (enrdf_load_html_response) | ||
| CH117071A (fr) | Solution colloïdale destinée à servir de véhicule-support à des substances radio-actives et en particulier à des émanations de radium. | |
| FR2514259A1 (fr) | Compositions pharmaceutiques a base d'acide alginique et de tris-(hydroxymethyl) aminomethane | |
| MoERK | GLEANINGS FROM THE GERMAN JOURNALS. | |
| FR2547499A1 (fr) | Medicaments contenant du dipropylacetate de calcium | |
| CH280752A (fr) | Procédé de préparation d'acide ptéroylglutamique. | |
| BE662142A (enrdf_load_html_response) | ||
| BE784531A (fr) | 1-phenyl biguanides et leur preparation | |
| FR2643637A1 (fr) | Complexe d'ion calcium avec au moins un acide gras insature, agent biomediateur comprenant un tel complexe, composition pharmaceutique l'incorporant et extraits de plantes ou d'organes d'animaux en contenant |